1. EXECUTIVE SUMMARY
2. MARKET SNAPSHOT
2.1. Market Overview
2.2. Market Definition
2.3. Scope of the Study
2.4. Market Segmentation
3. BUSINESS LANDSCAPE
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Industry Value Chain Analysis
3.6. Policies and Regulations
3.7. Strategic Recommendations
4. TECHNOLOGICAL OUTLOOK
5. BIOLOGICS OUTSOURCING SERVICES MARKET BY SERVICE TYPE
5.1. Introduction
5.2. Drug Development Services:
5.2.1. Cell Line Development
5.2.2. Process Optimization
5.2.3. Analytical Testing
5.3. Manufacturing Services:
5.3.1. Drug Substance Manufacturing
5.3.2. Fill/Finish Operations
5.3.3. Biosimilar Production
5.4. Regulatory & Compliance Services
5.5. Clinical Research Services:
5.5.1. Preclinical Studies
5.5.2. Phase I-IV Trials
5.6. Supply Chain & Logistics Services
6. BIOLOGICS OUTSOURCING SERVICES MARKET BY MOLECULE TYPE
6.1. Introduction
6.2. Monoclonal Antibodies (mAbs)
6.3. Recombinant Proteins
6.4. Vaccines
6.5. Cell & Gene Therapies
6.6. Others
7. BIOLOGICS OUTSOURCING SERVICES MARKET BY END-USER
7.1. Introduction
7.2. Pharmaceutical Companies
7.3. Biotechnology Firms
7.4. Academic & Research Institutions
8. BIOLOGICS OUTSOURCING SERVICES MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. Germany
8.4.2. France
8.4.3. United Kingdom
8.4.4. Spain
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. UAE
8.5.3. Others
8.6. Asia Pacific
8.6.1. China
8.6.2. Japan
8.6.3. India
8.6.4. South Korea
8.6.5. Thailand
8.6.6. Indonesia
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. WuXi Biologics
10.2. Lonza Group AG
10.3. Samsung Biologics Co., Ltd.
10.4. Thermo Fisher Scientific Inc.
10.5. Charles River Laboratories International, Inc.
10.6. Catalent, Inc.
10.7. Boehringer Ingelheim International GmbH
10.8. AGC Biologics
10.9. Fujifilm Diosynth Biotechnologies
10.10. Rentschler Biopharma SE
11. APPENDIX
11.1. Currency
11.2. Assumptions
11.3. Base and Forecast Years Timeline
11.4. Key benefits for the stakeholders
11.5. Research Methodology
11.6. Abbreviations
LIST OF FIGURES
LIST OF TABLES